NOKOMIS, Fla.--(BUSINESS WIRE)--When Rainbow Coral Corp. (OTCBB:RBCC) moved its biosciences division to Houston, Texas, it tapped into an economic hot bed. According to local economists, Houston’s biotechnology sector outpaced every other sector of the city’s economy last year.
One of the main drivers of the biotech industry’s success in Houston is the unique synergy between its healthcare and research institutions. Home to the largest medical center in the world, Houston offers a strong foundation of academic institutions, research centers, hospitals and clinics where health care professionals train and work. It’s the ideal setting for a new company like RBCC looking to tap into the heart of American biotech innovation.
RBCC’s rapidly growing business network in the region opens the door for the company to become a global player in biotech. Last week, the company proudly announced its new membership in BioHouston, a biotech consortium committed to helping Houston organizations facilitate technology transfer and research commercialization. There is no better group in the U.S. at helping emerging companies become global competitors in life science commercialization.
Thanks to the advanced thinking of some of the country's top research universities and creative entrepreneurs, RBCC is extremely optimistic that Houston’s biotech sector will continue to be tops in the region. The city offers the resources, culture and networks that RBCC needs to take a great idea from the laboratory to the marketplace.
For more information on Rainbow BioSciences, RBCC’s biotechnology division, please visit www.rainbowbiosciences.com/investors.
Rainbow BioSciences is working to develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) Amgen, Inc. (NASDAQ: AMGN) and Celgene Corp. (NASDAQ: CELG).
Follow us on Twitter at www.twitter.com/RBCCinfo.
About Rainbow BioSciences
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.